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Abstract. Atheroembolic renal disease (AERD) is part of a
multisystemic disease accompanied by high cardiovascular
comorbidity and mortality. Interrelationships between tradi-
tional risk factors for atherosclerosis, vascular comorbidities,
precipitating factors, and markers of clinical severity of the
disease in determining outcome remain poorly understood.
Patients with AERD presenting to a single center between 1996
and 2002 were followed-up with prospective collection of
clinical and biochemical data. The major outcomes included
end-stage renal disease (ESRD) and death. Ninety-five patients
were identified (81 male). AERD was iatrogenic in 87%. Mean
age was 71.4 yr. Twenty-three patients (24%) developed
ESRD; 36 patients (37.9%) died. Cox regression analysis
showed that significant independent predictors of ESRD were
long-standing hypertension (hazard ratio [HR]  1.1; P 
0.001) and preexisting chronic renal impairment (HR  2.12;
P  0.02); use of statins was independently associated with
decreased risk of ESRD (HR  0.02; P  0.003). Age (HR 
1.09; P 0.009), diabetes (HR 2.55; P 0.034), and ESRD
(HR  2.21; P  0.029) were independent risk factors for
patient mortality; male gender was independently associated
with decreased risk of death (HR  0.27; P  0.007). Cardio-
vascular comorbidities, precipitating factors, and clinical se-
verity of AERD had no prognostic impact on renal and patient
survival. It is concluded that AERD has a strong clinical
impact on patient and renal survival. The study clearly shows
the importance of preexisting chronic renal impairment in
determining both renal and patient outcome, this latter being
mediated by the development of ESRD. The protective effect
of statins on the development of ESRD should be evaluated in
a prospective study.
AERD is part of a multisystemic disease caused by showers of
cholesterol emboli from atherosclerotic aorta to many organs.
It may occur spontaneously or more often as a complication of
major medical or surgical procedures. The disease is usually
associated with poor renal and patient survival. In the last
decade, some clinical studies have increased our understanding
of AERD, enabling us to make premortem diagnosis. The
presence of a triad characterized by a precipitating event,
subacute renal failure, and peripheral cholesterol embolization
strongly suggests the diagnosis, which can be confirmed by the
biopsy of the target organs (1–6).
Although the clinical features of the AERD have been well
delineated, the predictors of the outcomes of the disease have
never been studied in a large population of patients. In addition
to the traditional risk factors for atherosclerosis, other factors
may be associated with the outcomes, including comorbidities,
precipitating factors, and clinical severity of the disease. How-
ever, the different and relative contribution of each factor is
unknown. In the present study, we prospectively followed up
95 consecutive patients with diagnosis of AERD to gain insight




After the retrospective analysis of our first series (7), we undertook
a longitudinal cohort study mainly aimed at identifying predictors of
outcome in patients with AERD. Patients attending the Renal Depart-
ment of Brescia, Italy, who had diagnosis of AERD from 1995 to
2002 were included in the study and prospectively followed.
Study Design
Data collection was prospective, which formed the basis of this
observational study. Demographic data, risk factors for atherosclero-
sis, comorbidities, and exposure to precipitating factors were recorded
at time of diagnosis of AERD. In all patients, serum creatinine
concentration was available shortly before the precipitating event for
iatrogenic forms and before the onset of symptoms for spontaneous
forms; at time of diagnosis of AERD; during the course of the acute
or subacute phase of disease. At follow-up clinic visits, serum creat-
inine concentration, clinical signs, and comorbidities were reassessed.
Demographic, clinical, and biochemical data recorded at different
times were entered into an electronic database after obtaining patient
informed consent.
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Definition of Comorbid Conditions
Comorbid conditions were evaluated at time of diagnosis of AERD.
Coronary artery disease was defined as symptomatic angina, positive
exercise stress-test result, positive coronary angiography, or evidence
of previous myocardial infarction. Cerebrovascular disease was de-
fined as clinical signs or radiologic confirmation of a transient isch-
emic attack or cerebrovascular accident. Peripheral vascular disease
was defined as symptoms of intermittent claudication, previous sur-
gery for lower-limb arterial insufficiency, and/or angiographic evi-
dence of significant stenosis in one or more blood vessels supplying
the lower limbs. Congestive heart failure was defined either as symp-
toms of relative pump failure, including episodes of pulmonary
edema, or echocardiographic description of systolic dysfunction or
cardiomegaly at chest x-ray. The presence of an abdominal aortic
aneurysm or of a renal artery stenosis ( 50% in one or both renal
arteries) was demonstrated by means of an angiographic examination.
Patients were considered to have diabetes if they had been given either
oral antidiabetic drugs or insulin. Patients were considered as smokers
both in case of actual or previous smoking habit. All smokers were
cigarette smokers with a consumption of more than 10 cigarettes per
day and with duration of smoking of  10 yr. Total cholesterol serum
level as well as the time of exposure to the hypertensive status were
available for all patients. Hypercholesterolemia was defined by pres-
ence of total cholesterol levels  220 mg/dl or by concomitant
administration of statins. Hypertension was defined as systolic or
diastolic BP of  140 mmHg or  90 mmHg, respectively, or if
anti-hypertensive drugs had been given.
Diagnostic Criteria
Patients were considered as having iatrogenic AERD if the follow-
ing criteria had been met: (1) renal function deterioration occurring in
atherosclerotic patients; (2) simultaneous ischemic changes to the
lower abdomen or extremities; (3) presence of one or more precipi-
tating factors. Histologic confirmation was available for the majority
of iatrogenic cases. Spontaneous form of AERD was diagnosed only
when skin, gastrointestinal, or renal biopsy documented cholesterol
clefts or, alternatively, when the funduscopic examination disclosed
retinal emboli. Signs of central nervous system involvement, gastro-
intestinal symptoms, presence of eosinophilia as well as the rate of
renal function deterioration were considered to evaluate the severity
of the disease. Detailed description of diagnostic criteria have been
reported elsewhere (2).
Definition of Renal Failure
Renal function was estimated using serum creatinine level (mg/dl)
and GFR, calculated using the abbreviated Modification of Diet in
Renal Disease (MDRD) formula (8). A preexisting chronic renal
impairment was defined by the presence of serum creatinine levels of
 1.5 mg/dl in men and  1.3 mg/dl in women; it was also very
conservatively defined as a calculated GFR  50 ml/min. With
respect to the clinical presentation of AERD, renal failure was defined
as acute if a sudden 50% increase of serum creatinine level was
evident within 1 wk after the precipitating event; as subacute if the
same amount of deterioration occurred in a stepwise fashion over 2 to
6 wk; as chronic if the patient had a stable renal impairment (2).
Variables of Interest and Outcome Measures
The major outcomes included end-stage renal disease (ESRD),
defined as need for permanent dialysis therapy, and death. Zero time
for survival analyses was the time of precipitating event for iatrogenic
forms of AERD and the date of the onset of symptoms for spontane-
ous ones. The covariates considered to test the potential association
with the development of ESRD and death included: (1) variables
present before zero time, including traditional risk factors for athero-
sclerosis (age, gender, hypertension, cholesterol levels, diabetes,
smoking) and comorbid conditions (coronary artery disease, cerebro-
vascular disease, peripheral vascular disease, congestive heart failure,
abdominal aortic aneurysm, renal artery stenosis, chronic renal im-
pairment); (2) factors acting closer to the onset of the AERD, such as
exposure to one or more precipitating factors; (3) markers of clinical
severity of the AERD, including degree of renal functional impair-
ment, defined as peak serum creatinine, modality of kidney function
deterioration (chronic versus acute and subacute renal failure), in-
volvement of organ systems other than kidney and skin, such as
gastrointestinal tract and central nervous system; (4) selected thera-
peutic variables including statins, which have a potentially protective
effect on plaque disruption, and steroids, used for the antiinflamma-
tory properties in a subset of patients with a short interval between the
procedure and onset of the disease.
Statistical Analyses
Baseline clinical characteristics of patients were compared by using
Pearson 2 test for categoric variables and t test or Mann-Whitney U
test for continuous variables, as appropriate. Logistic regression anal-
ysis was planned to determine the independent association between
the above-mentioned covariates with the development of ESRD. The
Kaplan-Meier product-limit technique was used to describe patient
and renal survival, and the log-rank statistics to test equality for strata.
Patients were censored if dialysis free or alive on the final observation
time (December 31, 2002). Cox proportional hazards regression mod-
els were planned to assess the independent effect of each factor on the
instantaneous probability of ESRD or death. Patients were censored as
in the descriptive analyses. The proportionality of the covariates was
evaluated using log minus log plots. All multivariate models were
developed by using both forward and backward elimination tech-
niques, including traditional risk factors for atherosclerosis, comor-
bidities, exposure to precipitating events, and markers of clinical
severity of the AERD. In the final models, all covariates were con-
sidered for controlling the effect of significant independent variables.
Estimated relative risks along with corresponding 95% confidence
limits and results of two-tailed likelihood ratio test of association are
reported for all regression covariates. P  0.05 for two-sided tests
were considered statistically significant. All calculations were made




From 1995 to 2002, AERD was diagnosed in 95 patients
(mean age, 71.4 yr; SD, 7.3; median, 71.7 yr; IQR, 67.1 to 76.5
yr) who were subsequently followed-up by the renal unit at
Brescia Hospital. The population included 81 men (85%). In
the 87 hypertensive patients (91.6%), the mean number of
years of exposure to hypertension were 10 (SD, 9 yr), with a
median of 7 yr (IQR, 4 to 15 yr). The mean total cholesterol
levels were 217 mg/dl (SD, 53 mg/dl); hypercholesterolemia
was found in 38 patients (40%), and 23 (24%) were on statin
treatment. Excluding hypertension, any cardiovascular disease
was present in 90% of the patients, and 14.7% were had
diabetes (n  14). AERD was spontaneous in 12 patients
(13%). Of 83 patients with iatrogenic form, 29% had a single
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precipitating factor, 44% had two precipitating factors, and
14% had three precipitating factors. The most common precip-
itating factor was angiography via the femoral artery (77.9%).
The diagnosis was clinical in 21 patients (22%); 72 patients
(76%) had histologically proven diagnosis (skin biopsy, 58
patients; renal biopsy, 5 patients; gastrointestinal biopsy, 4
patients; nephrectomy, 2 patients; autopsy, 2 patients; bone
marrow biopsy, 1 patient); in 2 patients (2%), the diagnosis
was confirmed by the only finding of retinal emboli. Demo-
graphic and clinical characteristics of the 95 patients are sum-
marized in Table 1.
Renal Function
Mean serum creatinine concentration shortly before the pre-
cipitating event or before the onset of disease (in spontaneous
forms) was 1.77 mg/dl (SD, 0.77 mg/dl; median, 1.5 mg/dl;
IQR, 1.2 to 2.0 mg/dl). The mean estimated GFR was 46.3
ml/min (SD, 18.6 ml/min; median, 45.4 ml/min; IQR, 30.4 to
63.5 ml/min). At that time, chronic renal impairment, based on
abnormal serum creatinine, was present in 57 patients (60%);
55 patients (58%) had an estimated GFR lower than 50 ml/min.
At the time of diagnosis, mean serum creatinine concentration
was 3.77 mg/dl (SD, 1.7 mg/dl; median, 3.5 mg/dl; IQR, 2.4 to
4.6 mg/dl). The mean peak serum creatinine was 5.84 mg/dl
(SD, 2.8 mg/dl; median, 5.1 mg/dl; IQR, 3.7 to 7.7 mg/dl),
corresponding to a mean estimated GFR of 14 ml/min (SD,
13.3 ml/min; median, 10.1 ml/min; IQR, 6.8 to 17.5 ml/min).
Thirty-five patients (37%) required dialysis therapy. The treat-
ment modality for the majority of the patients was hemodial-
ysis (23 patients; 66%); peritoneal dialysis was preferred in 12
patients. Twenty-one patients remained on maintenance dialy-
sis therapy, and 14 recovered sufficient renal function to stop
dialysis. Because of declining in renal function during follow-
up, two additional patients required maintenance dialysis.
Renal Survival
A final diagnosis of ESRD was made for 23 patients (24%).
These patients were more likely to have an abnormal basal serum
creatinine (34 versus 10%; P  0.011) and renal artery stenosis
(40.7 versus 19.6%; P  0.045) and were less likely to be under
statin treatment (4.3 versus 30.6%; P  0.011). Patients who
reached ESRD had significantly lower GFR at baseline, being the
median values (IQR) 33.7 (15.4) versus 49.8 (30.6) ml/min (rank
sum P  0.003; arithmetic mean difference, 12.9 ml/min; 95%
CI, 5.3 to 20.5 ml/min; P  0.001). Furthermore, they had a
significantly longer history of arterial hypertension, being the
median values (IQR) 10 (14) versus 5.5 (7) yr (rank sum P 
0.008; arithmetic mean difference 5.5 yr; 95% CI, 1.1 to 9.7 yr; P
 0.013). Logistic regression showed that preexisting chronic
renal impairment, evaluated using both serum creatinine levels
and GFR, and the years of exposure to hypertension significantly
predicted ESRD, independently of all the other confounders (gen-
der, presence of diabetes, and the other comorbidities). We then
manually added each variable of interest (precipitating factors, use
of steroids and statins, and markers of clinical severity of AERD)
to test if they improved the model fit. Only the use of statins was
retained in the final model (OR, 0.01; P 0.01). The same results
were obtained considering peak serum creatinine instead of the
preexisting chronic renal impairment (Figure 1). The results were
also confirmed considering time to event by both univariable
analysis and multivariable modeling. At univariable analysis, pa-
tients with preexisting chronic renal impairment (0.68 versus 0.90;
P  0.0005), presence of renal artery stenosis (0.61 versus 0.82;
P  0.0259), and those who were not given statins (0.74 versus
0.94; P  0.0192) had a significantly lower 1-yr cumulative
survival. The hazard for ESRD was increased by 8.6% per each
year of previous exposure to arterial hypertension, 82.8% per each
mg/dl of serum creatinine increase, while the use of statins con-
ferred a significant protective effect, reducing the hazard ratio
Table 1. Baseline patient characteristics, risk factors, and
clinical findingsa
Demographics and comorbidities






statin treatment 23 (24%)
coronary artery disease 69 (73%)
peripheral vascular disease 51 (54%)
cerebrovascular disease 35 (37%)
abdominal aorta aneurysm 40 (42%)
congestive heart failure 30 (32%)
chronic renal failure 57 (60%)
renal artery stenosis 27 (28%)




cardiovascular surgery 15 (16%)
anticoagulation/fibrinolysis 31 (33%)
Clinical presentation
iatrogenic forms 83 (87%)
acute renal failure 33 (35%)
subacute renal failure 44 (46%)
chronic renal failure 18 (19%)
cutaneous findings 82 (86%)
extrarenal (CNS and/or GIT) 24 (25.3%)
neurological changes 5 (5%)
gastrointestinal changes 12 (13%)
retinal emboli 10 (11%)




histologically proven 72 (76%)
retinal emboli 2 (2%)
a Variable values expressed as mean  SD and N (%), as
appropriate.
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(HR) to 0.031%. The presence of renal artery stenosis was asso-
ciated with a marginally significant increased risk of chronic
dialysis. Figure 2 graphically depicts the HR for ESRD, adjusted
for gender, age, diabetes, comorbidities, use of steroids, precipi-
tating factors, and markers of clinical severity of AERD. When
the peak serum creatinine (or the worse estimated GFR) was
introduced in the equation, this independent variable was the only
covariate retained in the model (adjusted HR associated with each
mg/dl of worse serum creatinine, 1.48; 95% CI, 1.23 to 1.80; P
0.001).
Patient Survival
The mean follow-up of the cohort as a whole was 61.53 mo
(95% CI, 48.28 to 74.78 mo), with a median survival of 49.05
mo (95% CI, 29.25 to 68.86 mo) and 487 patient-years at risk.
During the study, 36 patients (37.9%) died, and 59 patients
remained under active follow-up (7 event % patient-years at
risk). Of 36 patients who died, cause of death was ascertained
for 32 patients. Cardiovascular disease was the main cause of
mortality, accounting for 26 deaths (72%); 19 patients (52.7%)
died as a result of cardiac causes (myocardial infarction, 11
patients; arrhythmia, 3 patients; heart failure, 3 patients; sud-
den death, 3 patients) and 7 (19.4%) due to vascular causes
(stroke, 3 patients; atheroembolic intestinal infarction, 4 pa-
tients). Other causes of death in the study cohort were cachexia
(2 patients), infection (1 patient), acute severe pancreatitis (1
patient), malignancy (2 patients). One-year cumulative survival
was significantly longer in men than in women (0.86 versus
0.52; P  0.0036) and in patients without preexisting chronic
renal impairment (0.91 versus 0.76; P  0.0003) (Figure 3).
Conversely, shorter survival was borderline associated with a
history of diabetes (0.6 versus 0.86; P  0.0650) and heart
failure (0.75 versus 0.85; P  0.0441) and significantly asso-
ciated with the development of ESRD (0.61 versus 0.88; P 
0.0342). A beneficial effect of statins was also observed on
patient survival, although not statistically significant (0.9 ver-
sus 0.81; P  0.102). In the Cox regression model, only
gender, age, and diabetes were retained. Precipitating factors
and markers of clinical severity of AERD did not significantly
improve the model fit when added. Conversely, the develop-
ment of ESRD was independently associated with more than
doubling the risk of death (Figure 4). Even considering the
peak serum creatinine (or the worse GFR estimate), the final
equation did not change.
Discussion
There have been few studies of outcomes in patients with
AERD (2,3,6). They are all retrospective and do not resolve the
confusing relationships among traditional risk factors for ath-
erosclerosis, vascular comorbidities, and severity of AERD in
determining renal and patient outcome. Our study is the first
prospective study addressing this issue and provides important
insights into the likelihood of renal and patient mortality in
patients with AERD.
With respect to the ESRD outcome, the key findings were
threefold. First, preexisting chronic renal impairment was the
chief variable independently associated with increased proba-
bility of ESRD. The association of preexisting chronic renal
impairment with ESRD outcome in AERD patients is not
surprising, because the presence of renal dysfunction at disease
diagnosis is usually a predictor of poor renal outcome in all
renal diseases. In patients developing AERD, the preexisting
renal impairment is usually due to ischemic atherosclerotic
nephropathy, which frequently co-clusters with AERD (9).
Figure 1. Logistic regression models: odds ratios (OR) for ESRD adjusted for age, gender, smoking, cholesterol, comorbidities (heart failure,
diabetes, vascular diseases), eosinophilia, precipitating factors, markers of clinical severity, and use of steroids.
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This was confirmed in our study, where a number of patients
(28%) had renal artery stenosis. Of note, renal artery stenosis
was associated with an increased, although NS, risk of devel-
oping ESRD. Of interest, the second important finding of our
study was that long-standing hypertension exerted a signifi-
cant, negative effect on ESRD outcome. The deleterious im-
pact of each 10 yr of hypertension was comparable to that of
each mg/dl higher basal serum creatinine level. The adverse
effect of hypertension, a key factor affecting progression of
renal dysfunction in all chronic renal diseases (10), reinforces
the importance of the preexisting intrarenal vascular damage in
determining ESRD outcome. These findings seem to support
the view that the preexisting intrarenal vascular parenchymal
damage is the arbiter of renal outcome in patients developing
AERD. We can hypothesize that cholesterol embolic event acts
as a “second ischemic hit,” aggravating the preexisting intra-
renal vascular lesions and contributing to the development of
ESRD on ischemic grounds.
The third major finding was a protective benefit of statins,
because patients on statin treatment had a significant lower
risk for developing ESRD. To date, the role of statins in
AERD remains uncertain, because only occasional cases
have responded to lovastatin and simvastatin (11,12). Be-
cause deterioration in renal function over several weeks
observed in the majority of patients with AERD suggests an
ongoing embolic process, strategies should be developed to
stabilize ulcerated atherosclerotic plaques showering cho-
lesterol emboli into renal circulation. Recent studies have
demonstrated that statins possess, beyond cholesterol-low-
ering, antiinflammatory, and immunomodulatory properties,
which may contribute to plaque stabilization (13). We might
speculate that the beneficial effects observed with statin
treatment in our patients could be explained in the context of
the emerging evidence of statin-induced plaque stabilization
and regression (14,15).
Historically, patients with AERD are considered to have a
dismal outlook (1,2). An aggressive therapeutic approach,
however, with patient-tailored supportive measures, may be
associated with a more favorable clinical outcome (3). In our
study, the 1-yr and 2-yr patient survival rates were 82% and
73%, respectively. The major cause of death was cardiovascu-
lar. This was not surprising, considering the atherosclerotic
background of these patients. Most patients died from tradi-
tional cardiovascular events usually injuring the elderly ath-
erosclerotic patients. In a minority of patients, however, cause
of death was gastrointestinal ischemia, which occurred as a
direct consequence of disseminated microvascular obstruction
by cholesterol crystals. The proportional hazard analyses iden-
tified age, female gender, diabetes, and ESRD as the most
salient predictors of death. As expected, older age and diabetes,
which are well-recognized risk factors for atherosclerosis, were
associated with increased risk of death. However, the relation-
ship between female gender and patient mortality was an
unexpected finding, because male gender is one of the tradi-
tional markers of complicated atherosclerosis. The implication
of this finding, however, needs to be tempered by the small
number of female patients enrolled in the study. Undoubtedly,
the most important finding was the independent role of ESRD
as a strong predictor of mortality, being associated with a more
than doubled risk of death. In the present cohort, its effect was
Figure 2. Cox proportional hazards regression models: hazards ratios (HR) for ESRD adjusted for age, gender, smoking, cholesterol,
comorbidities (heart failure, diabetes, vascular diseases), eosinophilia, precipitating factors, markers of clinical severity, and use of steroids.
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similar to that of diabetes and of 12 yr of age. It is not surprising
that the patients developing ESRD should have increased mortal-
ity. The occurrence of ESRD is associated with a higher preva-
lence of traditional cardiovascular risk factors and with nontradi-
tional, specific risk factors related to uremia, including increased
extracellular fluid volume, electrolyte imbalance, anemia, and
higher levels of homocysteine (16). Finally, it should be reminded
that preexisting chronic renal impairment was the most striking
predictor of ESRD, which for its part, was found to be a key
determinant of patient mortality. This clearly emphasizes the
indirect role of preexisting chronic renal impairment in determin-
ing also patient outcome.
No difference was found in renal and patient survival be-
tween spontaneous and iatrogenic forms of AERD, and the
Figure 3. Crude survival plots by gender and preexisting chronic renal impairment. Crosses mark points of censor.
Figure 4. Cox proportional hazards regression models: hazards ratios (HR) for death adjusted for hypertension, smoking, cholesterol,
comorbidities (heart failure, vascular diseases), eosinophilia, precipitating factors, markers of clinical severity, and use of statins and steroids.
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exposure to more than one precipitating factor had no prog-
nostic impact. These findings contrast with those of some
authors (1,6) who suggest that iatrogenic forms were associ-
ated with worse prognosis. A possible explanation is that
patients with spontaneous form can have a more severe and
complicated underlying atherosclerosis that does not require
any precipitating factors to determine the showers of emboli.
Our study showed the high burden of cardiovascular morbidity
borne by patients with AERD, but we were unable to show that
the overall burden of cardiovascular comorbidity might in-
crease the risk for death or need for dialysis. We acknowledge
the limitations of this aspect of our analysis, because no at-
tempt was made to grade the severity of comorbid vascular
conditions. Our results may have been also influenced by the
patient population studied, because we studied patients with
severe AERD, representing the “tip of the iceberg” (2).
In summary, we found that AERD has a strong clinical
impact on both the patient and renal survival. Preexisting
chronic renal impairment seemed the most striking predictor of
ESRD, which in turn was found to be a key determinant of
patient mortality. These data clearly show that chronic renal
impairment at baseline can be considered the key to predict the
individual patient’s outcome. Our prospective observational
study precludes the establishment of causality. However, the
results can be used to develop interventional studies on the
basis of biologically plausible associations of specific risk
factors. The protective effect of statins suggests that these
drugs can be effective in altering the course of disease, and a
possible role of such a therapy should be evaluated in a proper
prospective study.
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